Tavalisse (fostamatinib) was granted approval by the Food and Drug Administration (FDA) for patients with chronic immune thrombocytopenia (ITP) after they had an insufficiencent response to another therapy.
Nutritional change may be a potential strategy to improve symptom burden and inflammation in patients with MPNs, whohave increased inflammatory cytokines, which contribute to symptoms such as fatigue, night sweats and bone pain, as well as low cholesterol and weight loss related to nutritional deficiencies.
For more than 20 years, Barbara Abernathy, Ph.D., has been living with cancer and its aftermath. She was diagnosed with a rare type of blood cancer collectively known as myeloproliferative neoplasms (MPNs), which transitioned into acute myeloid leukemia. In 2013, she underwent a stem cell transplantation — a lifesaving gift from a young man in Germany.
For years, many health care professionals noticed that patients with myeloproliferative neoplasms (MPNs) tend to experience thrombosis more than the average person. Now, a recent population-based study conducted in Sweden confirmed their suspicions.
Carole Brennan Miller, M.D., head of the Cancer Institute at Saint Agnes Hospital, explains what makes people with myeloproliferative neoplasms (MPNs) unique, and why she finds it interesting to work with them.
Susan Leclair, Ph.D., CLS (NCA), retired lab professor at University of Massachusetts, Dartmouth, discusses how moderating an online forum for patients with myeloproliferative neoplasms (MPNs) has inspired her.